Intravenous immunoglobulin in lupus panniculitis.
Systemic lupus erythematosus (SLE) is a disease of unknown cause that may involve one or many organ or systems. Skin involvement is a major feature in this disease, and a wide variety of skin conditions may be present. Lupus erythematosus panniculitis (LEP) constitutes a rare form of cutaneous lupus characterized by recurrent nodular or plaque lesions that can vary from a benign and mild course to a more disfiguring disease. Initial therapy includes corticosteroids, antimalarials, and azathioprine and, in refractory cases, two antimalarials in association, mycophenolate mofetil, or other immunomodulators. Intravenous immuglobulin (IVIG) is used in many autoimmune disorders, like in SLE, although clinical trials have not yet taken place. In this report, we review skin manifestations of SLE and their treatment, IVIG, and finally a case of LEP successfully treated with IVIG when other therapy modalities failed.
Espírito Santo
João
J
Departement of Medicine 1, Hospital Santa Maria, Lisbon, Portugal. joao.es@iol.pt
Gomes
M F
MF
Gomes
M J
MJ
Peixoto
L
L
C Pereira
S
S
Acabado
A
A
Freitas
J
J
de Sousa
G Vinhas
GV
D000328:Adult; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008875:Middle Aged; D015435:Panniculitis, Lupus Erythematosus / Q000188:drug therapy* / Q000503:physiopathology
D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents